China has released a new five-year development plan for the pharmaceutical industry, setting targets for innovative drugs, AI-driven manufacturing, supply-chain resilience, precision medicine and global cooperation through 2030.
China has unveiled its Pharmaceutical Industry Development Plan for the 15th Five-Year Plan Period, establishing a policy framework for the industry's development from 2026 to 2030.
The plan was jointly issued on August 28, 2026, by 10 government departments, including the Ministry of Industry and Information Technology (MIIT), the National Development and Reform Commission and the National Medical Products Administration. MIIT published an official interpretation of the plan on September 18.
Rather than introducing a single new regulatory requirement, the plan sets out the government's priorities for strengthening China's pharmaceutical industry over the next five years. Its focus covers innovation, industrial resilience, digital transformation, precision medicine, manufacturing efficiency, healthcare access and international cooperation.
For pharmaceutical manufacturers, API suppliers, medical-device companies and other businesses across the healthcare value chain, the plan provides important signals about where China's pharmaceutical industry is heading through 2030.
What Does China Want to Achieve by 2030?
The plan sets a series of development targets covering industry scale, innovation, enterprise growth and industrial clusters.
By 2030, pharmaceutical manufacturers above designated size are expected to generate more than RMB 3.5 trillion in annual revenue, while the innovative drug sector is targeted to achieve average annual growth of more than 20%.
The plan also aims to strengthen China's position in global pharmaceutical innovation. It sets targets for:
- At least five products with annual global sales exceeding US$1 billion;
- Average annual R&D intensity of more than 10% among listed pharmaceutical companies;
- First-in-class (FIC) drugs accounting for more than 25% of the global total;
- More than 200 innovative medical devices reaching the market;
- 50 pharmaceutical companies with annual revenue above RMB 10 billion;
- 20 pharmaceutical industrial parks reaching annual output values of RMB 1 trillion.
The targets are described as development expectations, rather than individual mandatory quotas for companies. Their significance lies in showing the direction of industrial policy and the areas expected to receive continued support and resources.
Four Major Shifts Behind the New Pharmaceutical Policy
The plan contains eight major areas and 25 key tasks, but these priorities can be broadly understood through four major shifts in China's pharmaceutical industry.
1. From Scale Expansion to Original Innovation
Innovation is placed at the center of the new plan.
China aims to strengthen original innovation capabilities, support innovative drugs and medical devices, make better use of industrial innovation platforms and accelerate the development of emerging technologies and products.
The emphasis on FIC drugs is particularly notable. The target of having FIC products account for more than 25% of the global total signals a stronger focus on original mechanisms and globally differentiated products, rather than simply increasing the number of pharmaceutical products.
This direction is also reflected in recent official analysis. MIIT experts noted that although China's clinical-stage pharmaceutical pipeline has expanded rapidly, challenges remain in original innovation, including a relatively limited supply of globally first-in-class drugs and continued homogeneity among some development programs.
For pharmaceutical companies, this means that R&D capabilities, differentiated technologies and the ability to translate new mechanisms into commercial products are likely to become increasingly important.
2. From Traditional Manufacturing to AI-Enabled and Greener Production
Digital transformation is another major priority.
The plan calls for deeper integration of artificial intelligence, digital technologies and pharmaceutical manufacturing, while also promoting greener production and greater efficiency.
The policy direction extends beyond factory automation. It covers the broader pharmaceutical value chain, including R&D, manufacturing, quality control, warehousing and logistics.
Recent policy analysis from MIIT also highlights technologies such as AI, industrial internet, big data, continuous synthesis and intelligent online quality control as tools for improving pharmaceutical manufacturing efficiency and lifecycle quality management.
For manufacturers, this could increase demand for intelligent production systems, digital quality-control technologies, advanced process equipment and data-driven manufacturing solutions.
3. From Individual Products to More Resilient Supply Chains
Supply-chain security is another core part of the plan.
China intends to strengthen industrial foundations, improve the resilience of pharmaceutical supply chains and continue developing key materials and components.
The previous planning period saw progress in high-end pharmaceutical excipients, reagents and consumables, medical-device raw materials and critical components. The new plan calls for further improvements in these areas.
This is particularly relevant to companies operating upstream of drug manufacturing.
APIs, pharmaceutical intermediates, excipients, reagents, specialized equipment and other critical inputs are closely connected to the industry's ability to develop and manufacture innovative medicines at scale.
An MIIT expert analysis published after the plan's release specifically highlighted the importance of strengthening the industrial foundation and supply-chain resilience. It also pointed to areas such as nucleic-acid drug raw materials, synthesis and purification equipment, and lipid nanoparticle delivery materials as examples of upstream capabilities supporting emerging drug modalities.
For international suppliers, China's continued investment in these areas could reshape sourcing opportunities and competition across the pharmaceutical supply chain.
4. From Conventional Treatment to Precision Medicine and Global Cooperation
The plan also identifies precision medicine as an important direction for future development.
Its priorities include precision prevention, advanced diagnostics and precision treatment, with the goal of creating a more integrated ecosystem around personalized healthcare.
At the same time, the plan calls for deeper international pharmaceutical cooperation, stronger global competitiveness and greater participation in global pharmaceutical innovation networks.
This means the policy is not focused solely on domestic production capacity. It also seeks to strengthen China's role in international pharmaceutical innovation and cooperation.
What Could the Plan Mean for Pharmaceutical and API Companies?
For companies across the pharmaceutical value chain, several areas are worth watching.
Innovative drug development is likely to remain a major growth area, particularly for companies with differentiated technologies, novel mechanisms and strong clinical translation capabilities.
Upstream pharmaceutical materials may also receive greater attention as the industry seeks to strengthen supply-chain resilience. API manufacturers, intermediate suppliers, excipient producers and companies providing specialized reagents and equipment are part of this broader industrial foundation.
Digital and AI technologies could become increasingly important in pharmaceutical manufacturing, process optimization and quality management.
At the same time, companies developing technologies related to precision diagnostics, targeted treatment, advanced drug delivery and emerging drug modalities may find themselves aligned with several of the plan's priority areas.
For international companies doing business with China, the policy also provides a useful reference for understanding the country's pharmaceutical manufacturing and innovation priorities over the next five years.
Implementation Will Require Cross-Department Coordination
The plan is designed to be implemented through coordination among multiple government departments.
MIIT said implementation will involve coordination across industrial development, science and technology, regulatory affairs, healthcare, medical insurance, finance and talent policies. The government also plans to improve review and approval mechanisms, refine pricing and payment policies, strengthen talent support and make greater use of industry organizations.
This cross-sector approach reflects the increasingly integrated nature of pharmaceutical development. Bringing an innovative drug to market requires more than R&D alone; it also depends on clinical development, manufacturing, regulatory review, reimbursement and commercial access.
Looking Ahead to 2030
China's new pharmaceutical industry plan sets a clear direction for the next five years: more original innovation, stronger industrial foundations, greater use of AI and digital technologies, more precise healthcare and deeper international cooperation.
For pharmaceutical manufacturers and suppliers, the most important change may be the growing connection between innovation and industrial capabilities.
Developing an innovative medicine is no longer only a question of discovering a new molecule. It also requires reliable raw materials, advanced manufacturing technologies, efficient clinical translation, digital production capabilities and access to global markets.
As the 15th Five-Year Plan moves into implementation, these priorities are likely to influence investment, technology development and supply-chain strategies across China's pharmaceutical industry through 2030.
